Table 2.
Patients characteristics
| Number of patients | 43 | |
|---|---|---|
| • Male | 21 | 48.8% |
| • Female | 22 | 51.2% |
| Primary malignant disease | 36 | 83.7% |
| • Mamma carcinoma | 11 | 30.6% |
| • Prostate carcinoma | 14 | 38.9% |
| • Multiple myeloma | 8 | 22% |
| • Lung carcinoma | 2 | 5.6% |
| • Leiomyosarcoma | 1 | 2.8% |
| Primary benign disease | 7 | 16.3% |
| • Osteoporosis | 7 | 100% |
| Oral bisphosphonate medication | 6 | 14% |
| • Aledronic acid | 6 | 100% |
| Intravenous bisphosphonate medication | 33 | 76.7% |
| • Zoledronic acid | 28 | 84.8% |
| • Pamidronic acid* | 3 | 9.1% |
| • Ibandronic acid* | 3 | 9.1% |
| Denosumab | 13 | 30.2% |
| Bisphosphonate followed by Denosumab** | 9 | 20.1% |
| Localisation | 43 | |
| • Upper jaw | 9 | 20.9% |
| • Lower jaw | 34 | 79.1% |
*One patient received pamidronic acid followed by ibandronic acid
**If patients received bisphosphonate followed by denosumab they also appear as bisphosphonate or denosumab patients